

Friday Satellite Symposia

Preceding the 64th ASH Annual Meeting and Exposition

Transforming How We Treat **SICKLE CELL DISEASE:** Holistic Approaches to Addressing Clinical Challenges Across the Patient's Lifespan

IN-PERSON + LIVE STREAMING SATELLITE SYMPOSIUM

FRIDAY, DECEMBER 9, 2022

11:00 AM - 1:30 PM CST

PROGRAM CHAIR

Biree Andemariam, MD

For more information, visit us at...

gotoper.com



STAY CONNECTED! Follow us @GoToPER and share your thoughts by using #gotoPER.

Dear Colleague:

On behalf of Physicians' Education Resource®, LLC (PER®), we would like to welcome you and thank you for choosing to attend **Transforming How We Treat Sickle Cell Disease: Holistic Approaches to Addressing Clinical Challenges Across the Patient's Lifespan**.

As clinicians, we are all aware of the significant morbidity and mortality associated with sickle cell disease (SCD), particularly related to vaso-occlusive crises (VOCs). Additionally, even independent of the VOCs, the disease causes silent damage that is progressive in nature. Importantly, there have been advances made in therapeutic options for SCD, both related to acute and longer-term therapy. Given the changing treatment landscape, it is essential for us all to keep abreast of the evolution of care for this disorder. This symposium is offered to help us do just that. It is designed to bring experts in the field to you to not only review data, but to also offer perspective.

In working with PER®, we strive to make this activity, along with all PER®-accredited continuing education (CE) activities, both useful and impactful for health care professionals like you who are involved in the care of patients with SCD.

If there is anything additional that you need, if you experience an issue, or if you have an idea for a future activity that would help you in the care of your patients, please let us know.

We could not have our accredited CE activities without you, and we appreciate your commitment to learning about the latest advancements in the treatment of SCD. Let's work together to make this an educational experience that will create a positive difference for our patients!

We hope you enjoy your experience at this first-class PER® symposium and that you can attend another PER®-accredited CE activity soon.

Regards,

Biree Andemariam, MD

Professor of Medicine

American Red Cross Endowed Chair in Transfusion Medicine

UConn School of Medicine

UConn Health

Farmington, CT

Jim Palatine, RPh, MBA

President

Physicians' Education Resource®, LLC

Cranbury, NJ

jpalatine@mjhllifesciences.com

AGENDA

11:00 AM	Welcome & Introductions	Biree Andemariam, MD
11:05 AM	Pre-Assessment	Biree Andemariam, MD
11:15 AM	SCD Disease Overview and Guidelines	Raffaella Colombatti, MD, PhD
11:45AM	Current and Emerging Treatments for SCD	Modupe Idowu, MD
12:20 PM	Optimizing the Transition from Pediatric to Adult Care	Nirmish Shah, MD
12:40 PM	Management of Complications and Comorbidities in Patients with SCD	Biree Andemariam, MD
1:10 PM	Post-Assessment	Biree Andemariam, MD
1:20 PM	Q & A	Biree Andemariam, MD
1:30 PM	Adjourn	

Upcoming PER® Conferences

2022

Inaugural International Congress Pediatric Oncology

December 16

2023

The 1st Annual Hawaii Lung: A Multidisciplinary Case-Based Conference™

Honolulu, HI

January 21

20th Annual Winter Lung Conference®

Hollywood, FL

February 3-5

19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

Dallas, TX

February 4

27th Annual International Congress on Hematologic Malignancies®

Miami Beach, FL

February 23-26

40th Annual Miami Breast Cancer Conference®

Miami Beach, FL

March 2-5

NYGU™ 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

New York, NY

March 10-11

8th Annual School of Gastrointestinal Oncology®

Orlando, FL

May 6

7th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards

May 6

14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies

May 13

22nd Annual International Congress on the Future of Breast Cancer® East

New York, NY

July 15-16

24th Annual International Lung Cancer Congress®

Huntington Beach, CA

July 27-29

22nd Annual International Congress on the Future of Breast Cancer® West

San Diego, CA

July 28-29

20th Annual Meeting of the International Society of Gastrointestinal Oncology®

Tempe, AZ

October 13-14

21st Annual School of Breast Oncology®

Atlanta, GA

November 2-4

41st Annual CFS®: Innovative Cancer Therapy for Tomorrow®

New York, NY

November 8-10

18th Annual New York Lung Cancers Symposium®

New York, NY

November 11



Virtual Conference



In-Person + Virtual Conference



In-Person Conference

Target Audience

This educational activity is directed toward hematologists, pediatricians, emergency medicine clinicians, pain management specialists, specialty NPs, PAs, RNs, and other health care providers involved in the management of patients with SCD. Other health care professionals interested in the treatment of SCD are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

- Outline the important components of successful pain management in patients with sickle cell disease (SCD)
- Evaluate the use of approved and emerging therapies alone or in combination for the management of patients with SCD
- Recognize the challenges of treating disease-related complications and comorbid conditions in patients with SCD
- Support the transition from pediatric to adult care based on an understanding of the evolving needs of patients with SCD
- Implement individualized and holistic management strategies in coordination with other specialists and health care providers involved with the patient

Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER[®] website by 12:00 PM EST Monday, December 12, 2022. To access these materials, please visit <https://www.gotoper.com/scd1222iss-esyl>.

How to Request Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit

<https://www.gotoper.com/scd1222iss-eval>.

The online evaluation and request for credit will be available immediately following the program and will remain available until January 23, 2023.

Accreditation/Designation of Credit

Physicians' Education Resource[®], LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource[®], LLC, designates this live activity for a maximum of 2.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource[®], LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.5 Contact Hours.

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Chiesi USA, Forma Therapeutics, a Novo Nordisk Company, and Vertex Pharmaceuticals.

Thank you for attending **Transforming How We Treat Sickle Cell Disease: Holistic Approaches to Addressing Clinical Challenges Across the Patient's Lifespan**

To register for upcoming accredited CE live activities or to view our online accredited CE activities, please visit www.gotoper.com.

We appreciate your attendance and look forward to seeing you at future PER[®] accredited CE activities.

Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: Nirmish Shah, MD and the staff of Physicians' Education Resource®, LLC.

The following individuals have relevant financial relationships with ineligible companies to disclose*:

Faculty	Grant/Research Support	Consultant	Speakers' Bureau	Other
Biree Andemariam, MD	Forma Therapeutics, Global Blood Therapeutics, Novartis	Agios, Aruvant, bluebird bio, CRISPR Therapeutics, CVS Accordant, Emmaus Life Sciences, Forma Therapeutics, Global Blood Therapeutics, Hemanext, Novartis, Novo Nordisk, Terumo BCT, Vertex Pharmaceuticals		
Raffaella Colombatti, MD, PhD	bluebird bio, Global Blood Therapeutics	Global Blood Therapeutics, Novo Nordisk	Addmedica, Forma Therapeutics, Global Blood Therapeutics, Novo Nordisk, Vertex Pharmaceuticals	
Modupe Idowu, MD, PhD	Agios, Forma Therapeutics, Global Blood Therapeutics, NIH, Novartis, Pfizer	Global Blood Therapeutics, Novartis	Global Blood Therapeutics	

**Information accurate at time of printing*

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

Physician Payments Sunshine Act

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.

Program Chair



Biree Andemariam, MD

Professor of Medicine

American Red Cross Endowed Chair in Transfusion Medicine

UConn School of Medicine

UConn Health

Farmington, CT

Biree Andemariam, MD, is a professor of medicine and the American Red Cross Endowed Chair in Transfusion Medicine at the University of Connecticut School of Medicine (UConn) with UConn Health in Farmington, Connecticut. She is a physician-scientist at UConn in the Division of Hematology/Oncology, founding director of the New England Sickle Cell Institute (NESCI) at UConn, and director of the Connecticut Bleeding Disorders Center.

Dr Andemariam joined UConn in 2007 as a physician-investigator and established the region's only adult sickle cell disease (SCD) program in 2009 through NESCI. NESCI's mission is to provide a medical home for adults with SCD as well as a transition destination for children with SCD. In addition to treating over 350 adults with SCD, the center is also home to numerous clinical and translational research studies. Dr Andemariam is lead principal investigator of 3 global SCD clinical trials. She is a sought-after clinical and scientific advisory board member for both large and small biopharmaceutical companies and has extensive experience in clinical trial design, development of primary and secondary endpoints, data analysis, patient/community engagement, and postmarketing awareness and educational strategies. During the COVID-19 global crisis, she mobilized and chaired an international committee of experts in the development and timely worldwide dissemination of guidelines on managing patients with SCD during the pandemic. Dr Andemariam is the immediate-past chief medical officer of the Sickle Cell Disease Association of America, Inc., (SCDAA) and serves on its board of directors. During her tenure at the SCDAA, she was awarded the Chairman's Award 3 times - 2019, 2020, 2022 - for her outstanding and dedicated board service largely centered around national programmatic development, disease education/awareness, legislative advocacy, corporate fundraising, and media engagement.

Faculty



Raffaella Colombatti, MD, PhD

Pediatric Hematologist

University of Padua

Padua, Italy

Raffaella Colombatti, MD, PhD, is a pediatric hematologist in the Department of Women's and Children's Health SDB at the University of Padua in Italy. She is an expert in the diagnosis, care, and treatment of complications in pediatric sickle cell disease (SCD).

Her main field of interest is red cell disorders, especially SCD. She has contributed to creating the Sickle Cell Veneto Region Reference Centre in Padua and is clinical coordinator of the local Universal Newborn Screening Program. She also is in charge of the General Hematology-Anemias Clinic.

In the past years, she has been involved in clinical research on SCD vasculopathy, cerebral and neurocognitive abnormalities, and brain function. Dr Colombatti is also interested in child health in Africa and is leading several projects in Guinea-Bissau, West Africa, in hematology and infectious disorders.

Faculty



Modupe Idowu, MD

Professor of Medicine
Division of Hematology
Director, Benign Hematology Section
Associate Program Director/Hematology/Oncology Fellowship
McGovern Medical School
UTHealth Houston
Houston, TX

Modupe Idowu, MD, earned her medical degree from the School of Medicine at Texas Tech University Health Sciences Center and completed a residency in internal medicine at the center, in Lubbock, Texas. She completed a fellowship in hematology at the University of Florida. Dr Idowu presently serves as a professor of medicine in the Division of Hematology and the director of the benign hematology section and associate program director of the hematology/oncology fellowship at the University of Texas Health Science Center, McGovern Medical School, in Houston, Texas. She is also the medical director of UT Physicians Comprehensive Sickle Cell Center. She is board certified in hematology.

Since joining McGovern Medical School, Dr Idowu has received accolades from her students and her peers. She has been awarded Dean's Teaching Excellence Award on a yearly basis since 2011.

Dr Idowu is an active member of the American Society of Hematology, American Federation for Medical Research, and the National Medical Association. Her clinical interests include sickle cell anemia, other anemias, thrombocytopenia, leukopenia, and bone marrow disorders. In addition to serving as principal investigator for more than 12 clinical trials, Dr Idowu is a reviewer for several journals, including Scientific Reports, Blood Advances, and Journal of Investigative Medicine. She has more than 20 articles published in peer-reviewed journals.



Nirmish Shah, MD

Associate Professor of Medicine and Pediatrics
Director of Sickle Cell Transition Program
School of Medicine
Duke University
Durham, NC

Nirmish Shah, MD, is currently involved in 3 main areas of research: novel therapeutic options for patients with sickle cell disease (SCD); the transition from pediatric to adult care for SCD; and the use of mobile technology to advance patient care for SCD.


Dr Shah has been most excited by his work on developing mobile apps and leveraging technology to improve patient care. He has conducted several studies using self-developed mobile apps to help patients with SCD, cancer, and those undergoing bone marrow transplants. For SCD, he has used apps to help patients with adherence to medications, education, and symptom monitoring. Understanding the subjective nature of symptoms and the intermittent data that comes through manual entries, he has now added wearable devices to passively acquire objective data. Dr Shah recently has been focusing on developing predictive algorithms through various machine learning techniques and has been able to accurately predict pain. Currently, he is working on refining and improving these algorithms through collaborations with multiple institutions and studies using the same platform.

Did you miss one of our sessions?


Check out the On-Demand Video Updates
from the Annual Hematology Meeting

—*Rapid Archive from*→ **NEW ORLEANS**


Archive will be available 24 hours after the live program ends.




**Optimized use of MRD in
Hematologic Malignancies**




State-of-the-Art CMV Care




**Emerging Treatments for
Anemia in CKD**



**Holistic Approaches in
Sickle Cell Disease Treatment**




**Diagnosis and Treatment of
Hemolytic Anemias**




**Optimized Treatments for
ALL in Adolescents and Adults**




**Multidisciplinary Management
of BPDCN**




**Maximizing Clinical Practice
for Hodgkin Lymphoma**



**State-of-the-Art Care for
MF and PV**




**Exploring Gene Therapy in
Hemophilia B**



**Diagnosing Uncommon
Hematologic Disorders**



**Novel Therapies to Prevent
and Treat GvHD**



**Novel Treatments for Indolent
and Aggressive B-Cell Lymphomas**



**Treating Transfusion-Related
Iron Overload**



Scan the QR code below
or visit gotoper.com/ash22
to view the symposia archive.

PER[®]
Physicians'
Education
Resource, LLC
gotoper.com